Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source examines alopecia areata, an autoimmune condition causing patchy hair loss, describing the current reliance on corticosteroid injections despite their severe side effects, and explores Ayurvedic treatments identified as Shaman and Shodhan for managing an equivalent condition called Indralupta.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This study reported that topical ω‐0‐acylceramide improved skin barrier function in Jack Russell Terriers with TGM1-deficient autosomal recessive congenital ichthyosis, normalizing skin pH and reducing transepidermal water loss.

This letter discusses androgenetic alopecia in men and the need for more research to understand its progression with age, reporting no new clinical results.

In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This study demonstrated that in mice, the absence of Jagged-1 expression in skin-resident regulatory T cells significantly delays wound healing by reducing the accumulation of neutrophils, highlighting the role of Jagged-1 in coordinating immune cell recruitment during injury.

This review explored treatment options for alopecia areata in the military health care system, evaluating the pathogenesis and impact of the condition as well as the efficacy and safety of FDA-approved JAK inhibitors, baricitinib and ritlecitinib.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This research letter discusses the use of Janus kinase inhibitors for treating lichen planopilaris, although specific results or conclusions from the study are not provided.

This review concluded that oral tofacitinib and adalimumab are promising treatments for cicatricial alopecia, showing effectiveness in improving signs and symptoms but requiring regular monitoring for adverse effects. The authors emphasize the need for further extensive studies to solidify these findings.

This study reports that in a single-case study, a 24-year-old female with alopecia areata experienced significant hair regrowth after undergoing seven sessions of Jalaukavacharana (leech therapy) along with Ayurvedic medication, suggesting these treatments may be beneficial for such cases.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This paper reviews the autoimmune disorder alopecia areata, its progression, and its significant emotional and psychological impact, but reports no new clinical findings.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This study observed that patient-physician alignment on alopecia areata severity largely followed Japanese Dermatological Association criteria, yet alignment on treatment satisfaction was lower, with lack of efficacy as the main dissatisfaction reason.

This case study reported significant hair regrowth in a young female patient with alopecia areata after 60 days of Ayurvedic treatment, including leech therapy and herbal medicines, demonstrating its potential effectiveness according to the authors' observations.

This study evaluated compounds from Jatropha cordata bark, finding that a sterol mixture and n-heptyl ferulate demonstrated notable anti-inflammatory activity in murine macrophage cells without toxicity, suggesting potential for treating chronic inflammation.

This study found that OR-101, a selective JAK3/TEK inhibitor, was associated with dose-dependent improvements in hair growth in humanized mice with alopecia areata, suggesting its potential as a treatment option.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

In this study, patients with alopecia areata displayed altered scalp microbiota compared to healthy controls, and treatment with JAK kinase inhibitors largely restored these microbial changes, providing insights into the potential role of the skin microbiome in alopecia areata.